Press releases

Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs anticoagulation alone.

The American College of Cardiology investor event on March 28 will feature a live webcast. Learn how to tune in or access the replay.

"Each brings deep leadership experience, strategic insight and a strong track record of value creation,” said CEO Mike Mahoney.

Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 46th Annual Health Care Conference on Tuesday, March 3, 2026. Mike Mahoney, chairman and chief executive officer, and...

“2025 was another exceptional year for Boston Scientific,” said Mike Mahoney, chairman and CEO.